Novo Nordisk launches Awiqli, described as the world’s first once-weekly basal insulin, in India. Multiple reports say the treatment is positioned for adults with type 1 and type 2 diabetes and is designed to reduce the injection burden by moving from a typical daily regimen to one injection per week. The company says this approach aims to cut the number of annual injections from 365 to 52 and may help address delays in starting insulin therapy. According to Business Line and The Hindu, Awiqli is imported from Denmark and is priced at ₹2,611 for a 1 ml pen, which corresponds to 700 insulin units. The Hindu also states that a once-weekly dose provides 70 insulin units and is priced at ₹261 (about $2.74). Times of India similarly frames the launch as a first-of-its-kind weekly insulin product in the country, though details beyond that are not provided in the supplied excerpt. The reporting collectively focuses on the product’s dosing frequency, target patient population, import sourcing, and pricing in India.